STOCK TITAN
  1. Home
  2. Sec-filings
  3. IKT
  4. [EFFECT] Inhibikase Therapeutics, Inc. SEC Filing

[EFFECT] Inhibikase Therapeutics, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
EFFECT
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Notice of Effectiveness
Effectiveness Date: June 27, 2025 4:01 P.M.
Form: S-3
CIK: 0001750149
Company Name: Inhibikase Therapeutics, Inc.
File Number: 333-288213

Source: View Original Filing on SEC EDGAR

Stock IKT logo
Inhibikase Therapeutics Inc

NASDAQ:IKT

IKT Rankings

#4717 Ranked by Market Cap
N/A Ranked by Dividends

IKT Latest News

Aug 19, 2025
Inhibikase Therapeutics Strengthens Leadership Team with Appointment of Timothy Pigot as Chief Commercial and Strategy Officer
Aug 14, 2025
Inhibikase Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Activity
May 14, 2025
Inhibikase Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Activity
Apr 14, 2025
Inhibikase Therapeutics Announces Appointment of David McIntyre as Chief Financial Officer
Mar 27, 2025
Inhibikase Therapeutics Announces 2024 Financial Results and Highlights Recent Activity

IKT Latest SEC Filings

Aug 28, 2025
[Form 3/A] Inhibikase Therapeutics, Inc. Amended Initial Statement of Beneficial Ownership
Aug 28, 2025
[Form 3/A] Inhibikase Therapeutics, Inc. Amended Initial Statement of Beneficial Ownership
Aug 28, 2025
[Form 4] Inhibikase Therapeutics, Inc. Insider Trading Activity
Aug 14, 2025
[SCHEDULE 13G/A] Inhibikase Therapeutics, Inc. SEC Filing
Aug 14, 2025
[10-Q] Inhibikase Therapeutics, Inc. Quarterly Earnings Report

IKT Stock Data

123.70M
59.40M
12.99%
78.04%
4.46%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
WILMINGTON